In summary, the combination of MSU42011 plus anti-PD1 or anti-PDL1 antibodies was efficacious in reducing tumor number, tumor size, and burden in the A/J mouse model of Kras-driven of lung cancer. This evidence concerns the gene KRAS and neoplasm.